Inflammatory bowel disease

American Journal of Managed Care

Volumn 10, Issue 8, 2004, Pages 544-552

  Martins, Noel B ^a,b   Peppercorn, Mark A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Apt 10 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDRESSIN; ALPHA4 INTEGRIN; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NICOTINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VERY LATE ACTIVATION ANTIGEN 4;

CHRONIC DISEASE; CLINICAL FEATURE; COLITIS; CROHN DISEASE; ECONOMIC ASPECT; ENTERITIS; HUMAN; MAJOR CLINICAL STUDY; MICROSCOPIC ANATOMY; PATHOGENESIS; POPULATION RISK; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; TISSUE DISTRIBUTION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PROBIOTICS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 4143121232     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Tremaine WJ. Collagenous colitis and lymphocytic colitis. J Clin Gastroenterol. 2000;30:245-249.
2. Marion JF, Rubin PH, Present DH. Differential diagnosis of chronic ulcerative colitis and Crohn's disease. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 2000:315-325.
3. Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 2000.
4. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14:309-317.
5. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002;35:151-156.
6. Loflus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:1-20.
7. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
8. Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut. 1998;29:990-996.
9. Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324;84-88.
10. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn's disease. Nat Genet. 2001;29:223-228.
11. Armuzzi A, Ahmad T, Ling K-L, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut. 2003;52:1133-1139.
12. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278:8869-8872.
13. Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology. 2003;125:47-57.
14. Sellon RK, Tonkonogy S, Schulte M, et al. Resident enteric bacteria are necessary for the development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224-5231.
15. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal luminal contents into excluded ileum. Gastroenterology. 1998;114:262-267.
16. Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997;40:619-622.
17. Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease: a case control study. Gut. 1988;29:352-357.
18. Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:364-371.
19. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutropnil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730-734.
20. Kwon JH, Peppercorn MA, Farrell RJ. Diagnostic features of inflammatory bowel disease. Gastroenterol Endosc News. 2002;53:28-29.
21. Miner PB. Clinical features, course, laboratory findings, and complications in ulcerative colitis. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 2000:299-304.
22. Lashner BA. Clinical features, lab findings, and course of Crohn's disease. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 2000:305-314.
23. Stebbing JF, Jewell DP, Kettlewell MC, Mortensen NJ. Recurrence and reoperation after strictureplasty for obstructive Crohn's disease: long-term results [corrected title] [published correction appears in Br J Surg. 1996;83:131]. Br J Surg. 1995;82:1471-1474.
24. Stebbing JF, Jewell DP, Kettlewell MC, Mortensen NJ. Recurrence and reoperation after strictureplasty for obstructive Crohn's disease: long-term results [corrected title] [published correction appears in Br J Surg. 1996;83:131]. Br J Surg. 1995;82:1471-1474.
25. Fazio VW. Toxic megacolon in ulcerative colitis and Crohn's colitis. Clin Gastroenterol. 1980;9:389-407.
26. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
27. Gillen CD, Walmsley RS, Prior P, et al. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590-1592.
28. Sachar DB. Cancer in Crohn's disease: dispelling the myths [comment]. Gut. 1994;35:1507-1508.
29. Blackstone MO, Riddell RH, Rogers BHG, Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology. 1981;80:366-374.
30. Su CC, Judge TA, Lichtenstein CR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:307-327.
31. Greenstein AJ, Janowitz HD, Sachar DB. The extraintestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55:401-412.
32. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology. 2000;118(suppl 1):S68-S82.
33. Svartz N. Salazopyrine: a new sulfanilamide preparation, A: therapeutic results in rheumatic polyarthritis, B: therapeutic results in ulcerative colitis, C: toxic manifestations in treatment with sulfanilamide preparations. Acta Med Scand. 1942;110:577-596.
34. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972;181:555-562.
35. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther. 1992;6:51-59.
36. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999;116:521-526.
37. Sutherland LR, Martin F, Green S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898.
38. Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology. 1988;94:1075-1079.
39. Campieri M, De Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis: a randomized controlled trial. Scand J Gastroenterol. 1990;25:663-668.
40. Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000;95:1749-1754.
41. Green JR, Lobo AJ, Holdsworth CD, et al, Abacus Investigator Group. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology. 1998;114:15-22.
42. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ. 1955;2:1041-1048.
43. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled dose-ranging study. Gastroenterology. 1996;110:45-51.
44. Thomson O, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med. 1998;339:370-374.
45. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
46. Dubinsky MC, Lamothe S, Yang ITY, et al. Pharmacogenomics and metabolite measurement of 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
47. Su C, Lichtenstein GR. Recent developments in inflammatory bowel disease. Med Clin North Am. 2002;86:1497-1523.
48. Feagan BC, Fedorak RN, Irvine EJ, et al, North American Crohn's Study Group Investigators. Comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med. 2000;342:1627-1632.
49. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999;94:1587-1592.
50. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998;93:442-448.
51. Sutherland L, Singleton J, Sessions J, et al. Double-blind placebo-controlled trial of metronidazole in Crohn's disease. Gut. 1991;32:1071-1075.
52. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995;108:1617-1621.
53. Madden MV, McIntyre AS, Nichols RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39:1193-1196.
54. Farrell RJ, Lamont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:41-62.
55. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639.
56. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108.
57. Gionchetti P, Rizzello F, Helwig V, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-1209.
58. Targan SR, Hanauer SB, van Deventer SJH, et al, Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
59. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
60. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
61. Probert CSJ, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002.
62. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608.
63. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
64. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-924.
65. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001;120:1330-1338.
66. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
67. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
68. Wu GD. Is there a role for PPARγ in IBD? yes, no, maybe. Gastroenterology. 2003;124:1538-1542.
69. Dubuquoy L, Jansson E, Deeb S, et al. Impaired expression of peroxisome proliferatory-activated receptor γ in ulcerative colitis. Gastroenterology. 2003;124:1265-1276.
70. Katayama K, Wada K, Nakajima A, et al. A novel PPARγ gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology. 2003;124:1315-1324.
71. Lewis JD. An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol. 2001;96:3323-3328.
72. Breuer RI, Soergel KH, Lashner BA, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut. 1997;40:485-491.
73. Asian A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol. 1992;87:432-437.
74. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Migliolo M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med. 1996;334:1557-1560.
75. Sachar DB. Indications for surgery in inflammatory bowel disease: a gastroenterologist's opinion. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 2000:611-615.
76. Dozois R, Kelly K. The surgical management of ulcerative colitis. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 2000:626-657.
77. Strong S, Fazio V. The surgical management of Crohn's disease. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 2000:658-709.